Natera Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Natera Inc 公司

Natera, Inc. 是一家診斷公司，專注於分子檢測服務的開發和商業化，將其技術應用於女性健康、腫瘤學和器官健康領域。其無細胞脫氧核糖核酸 (cfDNA) 技術結合了其分子檢測，可從小到單細胞的樣本中可靠地測量整個基因組的許多信息區域。該公司的產品包括 Panorama 無創產前檢測 (NIPT)、Vistara、Horizon 攜帶者篩查、Spectrum 植入前遺傳學、Anora 流產檢測、Empower 和 Prospera。該公司還提供 Constellation，這是一個基於雲的軟件平臺，使實驗室客戶能夠通過雲訪問公司的算法和生物信息學，以驗證和啓動基於公司技術的測試。其 NIPT 可篩查胎兒和雙胞胎妊娠的染色體異常，通常需要從母親抽血。

公司簡介

公司代碼NTRA

公司名稱Natera Inc

上市日期Jul 02, 2015

成立日期2007

CEOMr. Steven Leonard (Steve) Chapman

員工數量4424

證券類型Ordinary Share

年結日Jul 02

公司地址13011 Mccallen Pass

城市AUSTIN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編78753

電話16502499090

網址https://www.natera.com/

公司代碼NTRA

上市日期Jul 02, 2015

成立日期2007

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.37M

+1.01%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

-6.87%

Mr. Jonathan Sheena

Co-Founder, Director

327.94K

-0.90%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

174.95K

+0.22%

Mr. John Fesko

President, Chief Business Officer

92.34K

-0.37%

Mr. Solomon Moshkevich

President - Clinical Diagnostics

67.13K

-4.68%

Herman Rosenman ,CPA

Independent Director

62.93K

-4.50%

Dr. James I. (Jim) Healy, M.D., Ph.D.

Independent Director

43.15K

-0.49%

Mr. Steven Leonard (Steve) Chapman

Chief Executive Officer, Director

33.38K

-29.81%

Mr. Michael Burkes Brophy

Chief Financial Officer

14.49K

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.37M

+1.01%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

-6.87%

Mr. Jonathan Sheena

Co-Founder, Director

327.94K

-0.90%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

174.95K

+0.22%

Mr. John Fesko

President, Chief Business Officer

92.34K

-0.37%

Mr. Solomon Moshkevich

President - Clinical Diagnostics

67.13K

-4.68%

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Insurance carriers

1.57B

92.63%

Laboratory and other partners

97.21M

5.73%

Patients

27.88M

1.64%

地區USD

名稱

營收

佔比

United States

1.66B

97.69%

Europe, Middle East, India, Africa

23.88M

1.41%

Asia Pacific and Other

8.66M

0.51%

Americas, excluding U.S

6.62M

0.39%

業務

地區

業務USD

名稱

營收

佔比

Insurance carriers

1.57B

92.63%

Laboratory and other partners

97.21M

5.73%

Patients

27.88M

1.64%

股東統計

更新時間: 4月16日週三

持股股東

股東類型

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.04%

T. Rowe Price Associates, Inc.

4.89%

BlackRock Institutional Trust Company, N.A.

4.76%

JP Morgan Asset Management

4.31%

Farallon Capital Management, L.L.C.

3.26%

Other

73.74%

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.04%

T. Rowe Price Associates, Inc.

4.89%

BlackRock Institutional Trust Company, N.A.

4.76%

JP Morgan Asset Management

4.31%

Farallon Capital Management, L.L.C.

3.26%

Other

73.74%

股東類型

股東統計

佔比

Investment Advisor/Hedge Fund

37.24%

Investment Advisor

31.23%

Hedge Fund

16.26%

Individual Investor

3.26%

Family Office

2.73%

Family Office

2.73%

Family Office

2.69%

Research Firm

1.53%

Bank and Trust

1.40%

Other

0.93%

機構持股

更新時間: 1月20日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

1008

128.74M

95.25%

+14.58K

2024Q4

1001

128.40M

95.17%

-537.76K

2024Q3

896

125.06M

100.75%

-6.81M

2024Q2

850

125.13M

101.89%

-7.92M

2024Q1

798

124.30M

101.71%

-6.12M

2023Q4

781

119.55M

99.60%

-13.66M

2023Q3

787

122.52M

102.97%

-5.30M

2023Q2

792

116.72M

102.40%

-10.10M

2023Q1

788

115.81M

102.22%

-9.06M

2022Q4

777

112.51M

103.76%

+3.33M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

12.29M

9.09%

+878.30K

+7.70%

Dec 31, 2024

T. Rowe Price Associates, Inc.

6.65M

4.92%

+3.88M

+140.19%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

6.47M

4.78%

+285.61K

+4.62%

Dec 31, 2024

JP Morgan Asset Management

5.86M

4.34%

+1.78M

+43.64%

Dec 31, 2024

Farallon Capital Management, L.L.C.

4.43M

3.28%

-125.70K

-2.76%

Dec 31, 2024

Duquesne Family Office LLC

3.57M

2.64%

--

Dec 31, 2024

Wellington Management Company, LLP

3.24M

2.4%

+439.78K

+15.70%

Dec 31, 2024

Fred Alger Management, LLC

3.02M

2.23%

-994.18K

-24.78%

Dec 31, 2024

State Street Global Advisors (US)

2.99M

2.21%

-503.37K

-14.41%

Dec 31, 2024

RTW Investments L.P.

2.59M

1.92%

--

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

Global X Genomics & Biotechnology ETF

6.13%

Alger Mid Cap 40 ETF

6.07%

Invesco Dorsey Wright Healthcare Momentum ETF

5.71%

ARK Genomic Revolution ETF

5.41%

Franklin Genomic Advancements ETF

5.14%

First Trust Nasdaq Lux Digi Health Solutions ETF

5.04%

Invesco Biotechnology & Genome ETF

4.72%

Alger 35 ETF

4.36%

VanEck Biotech ETF

4.23%

WisdomTree BioRevolution Fund

3.67%

Global X Genomics & Biotechnology ETF

佔比6.13%

Alger Mid Cap 40 ETF

佔比6.07%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比5.71%

ARK Genomic Revolution ETF

佔比5.41%

Franklin Genomic Advancements ETF

佔比5.14%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比5.04%

Invesco Biotechnology & Genome ETF

佔比4.72%

Alger 35 ETF

佔比4.36%

VanEck Biotech ETF

佔比4.23%

WisdomTree BioRevolution Fund

佔比3.67%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Natera Inc

154.890USD

Natera Inc

154.890

概覽

公司